2026 Paul S. Aisen: Medicine Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	136	1944	1812	1105	1018	724	94757

Overview

Paul S. Aisen is affiliated with the University of Southern California in the United States and specializes in medical research with a strong focus on Alzheimer's disease. Their work spans multiple subfields within medicine, including physiology, psychiatry and mental health, cognitive neuroscience, molecular biology, and neurology.

The researcher's primary areas of study cover Alzheimer's disease research and treatments, dementia and cognitive impairment, functional brain connectivity, cholinesterase and neurodegenerative diseases, health systems and economic evaluations related to quality of life, advanced neuroimaging techniques, and neuroinflammation and neurodegeneration mechanisms.

Their recent published papers include:

"Lecanemab in Early Alzheimer's Disease," 2022, New England Journal of Medicine
"The Amyloid-β Pathway in Alzheimer's Disease," 2021, Molecular Psychiatry
"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease," 2022, The Journal of Prevention of Alzheimer s Disease
"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease," 2021, Nature Medicine
"Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease," 2020, Nature Communications

Frequent collaborators in their research include Clifford R. Jack, Michael Donohue, Laurel Beckett, Andrew J. Saykin, and John C. Morris. This network of co-authors reflects interdisciplinary cooperation in various aspects of neuroscience and clinical research.

Their work appears regularly in well-known publication venues such as Alzheimer's & Dementia, The Journal of Prevention of Alzheimer s Disease, Nature Communications, Scientific Reports, and Alzheimer s Research & Therapy. These outlets highlight the focus on neurodegenerative diseases and related clinical studies.

Best Publications

Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Reisa A. Sperling;Paul S. Aisen;Laurel A. Beckett;David A. Bennett

6553
Citations
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Clifford R Jack;David S Knopman;William J Jagust;Leslie M Shaw

5431
Citations
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

Clifford R Jack;David S Knopman;William J Jagust;Ronald C Petersen

4685
Citations
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease

Randall J. Bateman;Chengjie Xiong;Tammie L.S. Benzinger;Anne M. Fagan

4263
Citations
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Leslie M. Shaw;Hugo Vanderstichele;Malgorzata Knapik-Czajka;Christopher M. Clark

2374
Citations
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

R. C. Petersen;P. S. Aisen;Laurel A Beckett;M. C. Donohue

2370
Citations
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.

Bruno Dubois;Harald Hampel;Harald Hampel;Howard H. Feldman;Philip Scheltens

1996
Citations
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

RS Rachelle S. Doody;RG Ronald G. Rg Thomas;Martin Farlow;Takeshi Iwatsubo

1844
Citations
The Amyloid-β Pathway in Alzheimer's Disease.

Harald Hampel;John Hardy;Kaj Blennow;Kaj Blennow;Christopher Chen

1638
Citations
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Michael W. Weiner;Michael W. Weiner;Dallas P. Veitch;Paul S. Aisen;Laurel A Beckett

1406
Citations
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

Rachelle S. Doody;Rema Raman;Martin Farlow;Takeshi Iwatsubo

1320
Citations
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.

Michael Grundman;Ronald C. Petersen;Steven H. Ferris;Ronald G. Thomas

1235
Citations
Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial

Paul S. Aisen;Kimberly A. Schafer;Michael Grundman;Eric Pfeiffer

1196
Citations
Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis

Y. Iturria-Medina;R. C. Sotero;P. J. Toussaint;J. M. Mateos-Pérez

1176
Citations
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.

Joseph F. Quinn;Rema Raman;Ronald G. Thomas;Karin Yurko-Mauro

909
Citations
Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease

Pankaj D. Mehta;Tuula Pirttilä;Sangita P. Mehta;Eugene A. Sersen

865
Citations
The A4 Study: Stopping AD Before Symptoms Begin?

Reisa A. Sperling;Dorene M. Rentz;Dorene M. Rentz;Keith A. Johnson;Keith A. Johnson;Jason Karlawish

838
Citations
Amyloid deposition, hypometabolism, and longitudinal cognitive decline.

Susan M. Landau;Mark A. Mintun;Abhinay D. Joshi;Robert A. Koeppe

777
Citations
Comparing predictors of conversion and decline in mild cognitive impairment

S. M. Landau;Danielle J Harvey;C. M. Madison;E. M. Reiman

706
Citations
Testing the Right Target and Right Drug at the Right Stage

Reisa A. Sperling;Clifford R. Jack;Paul S. Aisen

679
Citations

Frequent Co-Authors

Ronald C. Petersen University of Pennsylvania

Michael W. Weiner University of California, San Francisco

Reisa A. Sperling Brigham and Women's Hospital

Clifford R. Jack Mayo Clinic

Michael C. Donohue University of Southern California

Andrew J. Saykin Indiana University

William J. Jagust University of California, Berkeley

John Q. Trojanowski University of Pennsylvania

Leslie M. Shaw University of Pennsylvania

Ronald G. Thomas University of California, San Diego

External Links

Personal website of Paul S. Aisen

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but want flexible options, online healthcare degrees offer a range of pathways. Today, many students pursue dnp programs without dissertation, which streamline the journey to advanced nursing leadership by removing some traditional academic barriers.

For those eager to join the workforce quickly, accelerated lpn programs allow you to become a Licensed Practical Nurse in less time and often through blended online study. Mental health roles are also in high demand—explore the fastest psychiatric nurse practitioner program options online, which can help you gain specialized skills to support this critical area.

For applicants interested in the business side of healthcare, a health administration degree online provides the foundation for careers in hospital management, insurance, and health policy. These flexible programs make advancing your career practical for busy professionals and those needing to balance work with further study.